The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review.

TitleBlood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review.
Publication TypeJournal Article
Year of Publication2014
AuthorsGiannakoulas, G., Mouratoglou S-A., Gatzoulis M. A., & Karvounis H.
JournalInt J Cardiol
Volume174
Issue3
Pagination618-23
Date Published2014 Jul 1
ISSN1874-1754
KeywordsAnimals, Biomarkers, Cross-Sectional Studies, Heart Defects, Congenital, Humans, Hypertension, Pulmonary, Natriuretic Peptide, Brain, Prospective Studies, Retrospective Studies, Vascular Endothelial Growth Factor A
Abstract

BACKGROUND: The development of pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is multifactorial with a number of biomarkers serving as mediators of neurohormonal activation [B-type natriuretic peptide (BNP) and its N-terminal-pro-fragment (NT-proBNP)], endothelial dysfunction [asymmetric dimethylarginine (ADMA)] and cellular proliferation [vascular endothelial growth factor (VEGF)].METHODS: We systematically reviewed the literature for trials studying the role of these biomarkers in the clinical evaluation, prognosis and management of patients with PAH related to CHD (CHD-PAH).RESULTS: Twenty-six studies were included in the systematic review, involving a total of 1113 patients with CHD-PAH. These patients had higher BNP, NT-proBNP and ADMA levels and higher VEGF expression when compared with healthy controls. Baseline and serial values of plasma levels of natriuretic peptides were shown to be significant predictors of survival. ADMA concentration was elevated in patients with CHD-PAH when compared with patients with simple CHD without PAH, whereas VEGF expression was particularly high in patients with CHD and persistent PAH after corrective surgery of the underlying heart disease.CONCLUSION: Right heart dysfunction, endothelial inflammation and proliferation are mirrored by plasma levels of the corresponding biomarkers among patients with CHD-PAH. There is early evidence to suggest that natriuretic peptides, in particular, may be a simple and effective tool for determining prognosis and timing for therapeutic interventions in patients with CHD-PAH.

DOI10.1016/j.ijcard.2014.04.156
Alternate JournalInt. J. Cardiol.
PubMed ID24814894

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.